If your patient is on a Mobile Insulin Dosing System (MIDS) treatment plan, the MIDS program can be ended once the patient reaches the optimal insulin dose and no longer needs to make adjustments based on the MIDS treatment plan.
NOTE: You also have the option to temporarily suspend a patient's MIDS program. To learn more, see How do I suspend or resume a patient's Glooko MIDS treatment plan?
In this article, you can learn about the two ways a MIDS treatment plan can be ended:
Set an end date in a patient's MIDS treatment plan
When configuring the MIDS treatment plan, you will be required to select an End Date so that a patient's MIDS program will automatically be terminated once a specific date has been reached. To learn more about creating and prescribing treatment plans, see Create and prescribe a Glooko MIDS treatment plan to a patient.
When that date is reached and the MIDS program is terminated, the patient will receive a notification via his or her Glooko mobile app that the program has been ended. The MIDS History screen will also display a status of "Ended: MIDS ended by provider" and there will be an entry added to the Patient Adjustments table.
Manually end a patient's MIDS program
If you would like to end the patient's MIDS program manually, you can do so at any time.
To manually end a patient's MIDS program:
- Click the MIDS tab within a patient's account.
- At the top-left of the MIDS History screen, click End Program to manually end the patient's MIDS program.
After ending the MIDS program, the patient will receive a notification via his or her Glooko mobile app that the program has been ended. The MIDS History screen will also display a status of "Ended: MIDS ended by provider" and there will be an entry added to the Patient Adjustments table.
TIP: After ending a patient's MIDS program, you can restart the patient on MIDS at any time by clicking Restart Program at the top-left of the MIDS History screen. The patient will need to be started on a new treatment plan.
*Please note: MIDS is currently only available in the U.S.